A Multimedia Educational eHealth Source™

Finding the Path in Alzheimer’s Disease

Early Diagnosis to Ongoing Collaborative Care

Suggested Readings

2020 Alzheimer’s disease facts and figures.

Alzheimer’s Association.

EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease.

Budd Haeberlein S, von Hehn C, Tian Y, et al. Presented at: 12th Clinical Trials on Alzheimer’s Disease; December 4-7, 2019; San Diego, CA.

Neuroinflammation in Alzheimer’s disease: current evidence and future directions.

Calsolaro V, Edison P. Alzheimers Dement. 2016;12(6):719-732.

Alzheimer’s disease prevention: from risk factors to early intervention.

Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimers Res Ther. 2017;9(1):71.

A practical algorithm for managing Alzheimer’s disease: what, when, and why?

Cummings JL, Isaacson RS, Schmitt FA, Velting DM. Ann Clin Transl Neurol. 2015;2(3):307-323.

Revising the definition of Alzheimer’s disease: a new lexicon.

Dubois B, Feldman HH, Jacova C, et al. Lancet Neurol. 2010;9(11):1118-1127.

Update on Alzheimer’s disease therapy and prevention strategies.

Graham WV, Bonito-Oliva A, Sakmar TP. Annu Rev Med. 2017;68:413-430.

Alzheimer’s disease: the amyloid cascade hypothesis.

Hardy JA, Higgins GA. Science. 1992;256(5054):184-185.

Alzheimer’s disease: the amyloid hypothesis on trial.

Harrison JR, Owen MJ. Br J Psychiatry. 2016;208(1):1-3.

Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers.

Jack CR Jr, Knopman DS, Jagust WJ, et al. Lancet Neurol. 2013;12(2):207-216.

A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers.

Jack CR Jr, Bennett DA, Blennow K, et al. Neurology. 2016;87(5):539-547.

Molecular and cellular basis of neurodegeneration in Alzheimer’s disease.

Jeong S. Mol Cells. 2017;40(9):613-620.

Cognitive symptoms of Alzheimer’s disease: clinical management and prevention.

Joe E, Ringman JM. BMJ. 2019;367:l6217.

The diagnosis and management of mild cognitive impairment: a clinical review.

Langa KM, Levine DA. JAMA. 2014;312(23):2551-2561.

Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older.

Larson EB, Wang L, Bowen JD, et al. Ann Intern Med. 2006;144(2):73-81.

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease.

Panza F, Lozupone M, Logroscino G, Imbimbo BP. Nat Rev Neurol. 2019;15(2):73-88.

The amyloid hypothesis of Alzheimer’s disease at 25 years.

Selkoe DJ, Hardy J. EMBO Mol Med. 2016;8(6):595-608.

Treatment of early AD subjects with BAN2401, an anti-Aβ protofibril monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline.

Swanson CJ, Zhang Y, Dhadda S, et al. Alzheimers Dement. 2018;14(suppl 7):P1668-P1668.

Potential new approaches for diagnosis of Alzheimer’s disease and related dementias.

Turner RS, Stubbs T, Davies DA, Albensi BC. Front Neurol. 2020;11:496.

Finding the Path in Alzheimer’s Disease

Early Diagnosis to Ongoing Collaborative Care

Relevant Resources

Updates on the Diagnosis and Management of Alzheimer's Disease

Screening, Imaging, and Emerging Treatment Strategies

Expert Consult Series in Multiple Sclerosis

Updates, Clinical Scenarios, and Future Directions

Moving Forward in Alzheimer’s Disease

New Management Paradigms for Patients and Healthcare Systems

Clinical Issues in Alzheimer's Disease

Debates and Discussions About Diagnosis, New Therapies, and Health Care Delivery